Formoterol/fluticasone propionate

Drug Profile

Formoterol/fluticasone propionate

Alternative Names: Abriff; Fluticasone propionate/formoterol fumarate; Fluticasone/formoterol; Flutiform; flutiform K-Haler; Flutiformo; Flutiform™ HFA-MDI; Formoterol fumarate/fluticasone propionate; Iffeza; KRP-108

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SkyePharma PLC
  • Developer Kyorin Pharmaceutical; Mundipharma International; Mundipharma Research; SkyePharma PLC; Vectura
  • Class Antiallergics; Antiasthmatics; Ethanolamines; Glucocorticoids; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Asthma; Asthma

Highest Development Phases

  • Marketed Asthma
  • Phase III Chronic obstructive pulmonary disease

Most Recent Events

  • 08 Aug 2017 Kyorin Pharmaceutical initiates a phase III trial for Asthma (In children, In adolescents) in Japan (JapicCTI-173632)
  • 05 Jul 2017 Kyorin Pharmaceutical plans a phase III trial for Asthma (In children, In adolescents) in Japan (JapicCTI-173632)
  • 03 Jul 2017 Kyorin Pharmaceutical plans a phase III trial for Asthma (In children, In adolescents) in Japan (JapicCTI-173633)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top